Table of contents


On 26 November 2009, orphan designation (EU/3/09/699) was granted by the European Commission to LFB-Biotechnologies, France, for recombinant chimeric monoclonal antibody against CD20 for the treatment of chronic lymphocytic leukaemia.

The sponsorship was transferred to Cambridge Regulatory Services Ltd, United Kingdom, in May 2018.

The sponsorship was transferred to CambPharma Solutions (CY) Limited, Cyprus, in July 2019.

Key facts

Active substance
Recombinant chimeric monoclonal antibody against CD20
Disease / condition
Treatment of chronic lymphocytic leukaemia
Date of first decision
EU designation number

Sponsor's contact details

CambPharma Solutions (CY) Limited
Aigyptou 36
Larnaca 6030

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating